Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$406.0K+59.22%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Laura E. Niklason
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 184
- Beta
- 2.45
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -8.80
Financials
Revenue
$406.0K+59.2%Net Income
$-36.80MEBITDA
$-33.14MFree Cash Flow
$-22.16MEPS (diluted)
$-0.16Shares Outstanding (diluted)
234.18M+127.4%Operating Expenses
$26.17MCash & Debt
$79.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.04M | $-40.83M | $-0.26 |
| 2024 | $0.00 | $-148.70M | $-1.26 |
| 2023 | $0.00 | $-110.78M | $-1.07 |
| 2022 | $1.56M | $-11.96M | $-0.12 |
| 2021 | $1.26M | $-26.48M | $-0.66 |
| 2020 | $1.49M | $-66.52M | $-5.52 |
| 2019 | $6.19M | $-85.42M | $-4.25 |
Valuation
HUMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-48.39%Social Signal Score
Mentions (12)
- Newszacks.com·4d ago·Positive
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·8d ago·Negative
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercializatio…
View source ↗ - Newszacks.com·10d ago·Positive
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
View source ↗ - Newszacks.com·17d ago·Neutral
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
View source ↗ - Newszacks.com·18d ago·Neutral
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newsglobenewswire.com·27d ago·Negative
…inues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has authorized an extension of the expiration dating period for Symvess® (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated a…
View source ↗ - Newsglobenewswire.com·43d ago·Negative
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions – Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results – Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –
View source ↗ - Newsglobenewswire.com·49d ago·Negative
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” – Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Humacyte Q2 Earnings Call Highlights Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.09 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.16 vs $-0.11miss
- Wed, May 13$-0.09 vs $-0.10beat
- Fri, Mar 27$-0.13 vs $-0.13beat
- Wed, Nov 12$-0.14 vs $-0.17beat
- Mon, Aug 11$-0.24 vs $-0.15miss
- Tue, May 13$0.28 vs $-0.19beat
Estimates and results for HUMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HUMA officers and directors.
- Bought
- $308k
- Sold
- $37.2m
17 trades
27 trades
- Jones Keith Anthonybought
- Jones Keith Anthonybought
- Jones Keith Anthonybought
- Sebelius Kathleenbought
- Constantino Michael T.bought
- Sander Dale A.sold
- Parikh Shamik Jsold
- Dougan Brady Wsold
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (867d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jun 14, 2024 (42d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 15, 2024 (15d later)Sell$50,001 - $100,000
- Thomas Hawley Tubervillesenate · AL · disclosed Apr 15, 2024 (25d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Mar 15, 2024 (32d later)Buy$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed Feb 14, 2024 (26d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 14, 2023 (20d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Apr 8, 2022 (9d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.